Tranilast: Phase I data

In a placebo-controlled Phase I trial in 46 healthy volunteers, 300, 600 and 900 mg/day tranilast significantly reduced mean sUA from baseline to day 7 by 24%, 57% and 66%, respectively. Patients received total daily doses of 300, 600 or 900 mg tranilast between once- or twice-daily regimens. Nuon said there was no difference in once- and twice-daily administration. Additionally, once-daily low-, mid- and high-dose tranilast significantly increased total 24 hour urinary uric acid excretion on day 7 by 132, 159 and 261 mg, respectively, and increased fractional excretion of uric acid by 4.6%, 17.9% and 31.8%. Data were presented at the European League Against Rheumatism meeting in Rome. ...